• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Proof-of-Principle Setup for Delivery of Relenza? (Zanamivir) Inhalation Powder to Intubated Patients

tetano

Editor, Senior Moderator
J Aerosol Med Pulm Drug Deliv. 2015 May 14. [Epub ahead of print]
[h=1]A Proof-of-Principle Setup for Delivery of Relenza? (Zanamivir) Inhalation Powder to Intubated Patients.[/h] Leung SS[SUP]1[/SUP], Parumasivam T, Tang P, Chan HK.
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] A fatal incident was reported when a mechanical ventilated patient received nebulization of a reconstituted Relenza[SUP]?[/SUP] formulation. We propose a delivery system to introduce Relenza and other inhalation dry powders to intubated patients to avoid accidental fatalities in the future.
[h=4]METHODS:[/h] This is a bench study demonstrating the feasibility of a delivery system to introduce dry powder of Relenza to intubated patients. A dry powder inhaler placed within a delivery chamber was actuated by compressing a ventilation bag to disperse powder into a tracheal tube. The performance of two inhalers, a Diskhaler[SUP]?[/SUP] and an Osmohaler[SUP]?[/SUP], were compared. The effects of the length and size of the tracheal tube on the powder output and sizing of emitted powder were investigated using the more efficient Osmohaler[SUP]?[/SUP].
[h=4]RESULTS:[/h] The efficiency of Osmohaler in delivering Relenza to the distal end [delivered dose=30.2?0.2% and fine particle fraction (FPF)=14.5?1.7%] was significantly higher than the Diskhaler (delivered dose=18.1?4.7% and FPF=3.4?2.1%). While no differences in the delivered dose and FPF were observed between the tracheostomy and endotracheal tubes of the same internal diameter, a larger endotracheal tube (9.0 mm internal diameter) gave a 6% higher FPF compared with the smaller counterpart (7.0 mm internal diameter).
[h=4]CONCLUSION:[/h] The dry powder delivery system has been demonstrated to be capable of delivering Relenza formulation to the distal end of tracheal tubes with a reasonable delivered dose and FPF. It would be necessary for further investigation into incorporating the proposed powder delivery system within a mechanical ventilator, as well as animal and clinical studies to prove its applicability to deliver zanamivir dry powder to ventilated influenza patients in the intensive care setting.


[h=4]KEYWORDS:[/h] dry powder inhaler; endotracheal tube; influenza virus A (H1N1); tracheostomy tube; ventilated patients

PMID: 25974393 [PubMed - as supplied by publisher]
 
Back
Top Bottom